Carotenemia | Treatment & Management | Point of Care (2024)

Tools

Back To Search Results

Author: Yasser Al Nasser Author: Zohaib Jamal Editor: Mohammed Albugeaey

Updated: 6/12/2023 7:51:02 PM

Introduction

First described in 1919 by Hess and Meyers, carotenemia is the medical terminology describing yellow-orange skin pigmentationdue to high carotene levels in the blood.[1]Excessive consumption of fruitsand vegetables high in carotene content is often the culprit.[2]Historically, carotenemia is a relatively old condition mentioned in a fewold medical case reports. This condition was also reported during World War 1 andWorld War 2, when people mostly consumed a plant-baseddiet due to food shortages and famine.[3]Carotenoids are organic compounds found in various plants and food items. Beta-Carotene is the main carotenoid found in plants and is more often responsible for this condition.[4]Carotenemiais often first encountered by primary care providers. Although benign, this condition is often confused with jaundice, leading to unnecessary investigations.

The condition of carotenemia is benign; however, it can lead to a wrong diagnosis of jaundice.Orangenessmay alsobear a significant symbolic significance.[5]Carotinemia was originallyobserved as xanthosis diabetica by von Noorden in 1904, who noted it to be more prominent on the palms and soles and in the nasolabial folds.[6]

Etiology

Register For Free And Read The Full Article

Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.

  • Carotenemia | Treatment & Management | Point of Care (2) Search engine and full access to all medical articles
  • Carotenemia | Treatment & Management | Point of Care (3) 10 free questions in your specialty
  • Carotenemia | Treatment & Management | Point of Care (4) Free CME/CE Activities
  • Carotenemia | Treatment & Management | Point of Care (5) Free daily question in your email
  • Carotenemia | Treatment & Management | Point of Care (6) Save favorite articles to your dashboard
  • Carotenemia | Treatment & Management | Point of Care (7) Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Already have an account? Log in

Etiology

Ingestion is the main source of carotenoids in the human body. Excessive ingestion (greater than 30 mg aday) for a prolonged period could lead to carotenemia.[7]A high levelof caroteneisfound in certain fruitsand vegetables. Fruits include apricot, cantaloupe, mango, orange, papaya, peaches, and prunes. Vegetables includecarrots, green beans, asparagus, broccoli, cucumber, lettuce, parsley, spinach, squash, mustard, pumpkins, kale, and sweet potatoes. Other food items with high carotene include butter, eggs, milk, and palm oil.[8]Although diet is often the culprit,cases of carotenemia havebeen reported in inheriteddisorders with the inability to convert carotene to vitamin A due to a deficiency in the beta-carotene-15-15'-dioxygenase enzyme.[9][3]

Diet-associated carotenemia is observed most commonly in infants and young children.[10] Mothers could also unknowingly induce carotenemia by feeding their infants excessive amounts of carrots in commercial food preparations.[2] Additionally, vegetarians are more prone to develop carotenemia than nonvegetarians. Consumption of carotene-rich nutritional supplements could also lead to this condition.[11]

Diseases, including hypothyroidism, hepatic disorders, diabetes mellitus, anorexia nervosa, and renal diseases, could also lead to carotenemia.[12]

Epidemiology

Although prevalencedata is scarce, carotenemia is not an uncommon presentation to pediatricians and family physicians. A Sri Lankan study found a prevalence of carotenemia of 2% among 615 children on a high carotenoid-containing diet.[13]The age of presentation varies, but it primarily presents in children. A study from Glasgowfound that the median age at presentation was 13 months, with a range of 7 months to 11 years. However, it mayalso be encountered in other age groups.[14]

Another study reported a much higher prevalence(approximately 22%) of carotenemia among children with mental disabilities. The authors commented it might be due to the different modes and types of feeding they received compared to healthy children.[15]

Pathophysiology

Carotenoids are organic hydrocarbonsmainly found in plant sources.Beta-carotene is the main carotenoid found in plants. Other carotenoids include alpha-carotene, beta-cryptoxanthin,lutein, andlycopene.[13]Beta-carotene is convertedinto vitamin A through 2 key enzymes, 15-15`-carotenoid dioxygenase, and beta-carotene-15-15'-dioxygenase.[16]Carotene serves as themain precursor of vitamin A in humans. Itis mainly absorbed in the proximal small intestine into the portal circulation.Around 10% of ingested carotene is absorbedwithout conversion andis carried into the portal circulation to the liver.[14]Fortunately, hypervitaminosis A does not occur with excess carotene ingestion, as the body convertsa limited quantity of carotene to vitamin A daily.[17]Carotene has a high affinity to fat and gets deposited in the corneum contributing to yellow skin discoloration and sparing mucus membranes if blood levels are excessively high.[8]

Many individuals with diabetes mellitus have increased serum carotene levels; however, only 10% of these patients have yellowing of the skin. Carotenemia could be associated with hyperlipidemia, restricted dietary habits, or adeficient hepaticconversion of carotene into vitamin A.

The commonly accepted pathophysiological mechanism underlying carotenemia in hypothyroidism is a deficient conversion of carotene into vitamin A, as well as hypercholesterolemia.The thyroidhormone is an antagonist to vitamin A andmediates its rate of catabolism. The consumption of vitamin A is reduced in hypothyroidism, and the conversion rate from carotene to vitamin A is decelerated.

Anorexia nervosa is also associated with carotenemia.[18] Carotenemia in patients with anorexia nervosa is associated with hypercholesterolemia, a reversible defect in carotene to vitamin A conversion. Furthermore, it could also be due to a normal carotene intake in the presence of a reduced requirement.

History and Physical

A good history and physical exam arekey and often lead to the diagnosis. The following are the main items that should be addressed in the patient interview and physical examination.

History

A detailed history shouldbe taken,including dietary history. The focusshould be on the history of food consumption with high carotene with the estimationof the amount taken and duration. In addition, screening shouldbe done for other conditions that could present with carotenemia, such as diabetes, anorexia, hypothyroidism, and liver and kidney diseases.

Metabolic carotenemia with no history of surplus carotene intake could be because of a genetic abnormality in the metabolism of carotenoids. Amenorrhea is also found to be associated with carotenemia. This is seen in vegetarians mainly. Patients may present with pruritus, abdominal pain, fatigue, and weight loss due to one of the rarer causes of carotenemia.[19]Pica, commonly seen in people with iron deficiency, could cause a compulsion to eat huge amounts of carrots, possibly leading to carotenemia.[20]

Physical Examination

Yellow-orange skin pigmentationis the hallmark of the condition. Pigmentationspares the sclera and mucous membranes (unlike jaundice) and concentratesin the palms, soles, forehead, tip of the nose, and nasolabial folds.[1]Yellow pigmentation often appears first in these areas, progressing gradually over the entire body.[21]Occasionally, carotenemia may also present with the coloration of the palate. It should be noted that the conjunctivae and oral mucosa lack stratum corneum. The pigmentary changes result from the accumulation of carotene in the stratum corneum. Examiners should also seek signs of diabetes, anorexia, and liver and kidney diseases.Children presenting with rarer causes of carotenemia unrelated to the diet may have physical signs suggestive of that specific disease process. Orange coloration in trichrome vitiligo may be due to carotenemia.[22]

Evaluation

Lab investigations are generally not required in establishing the diagnosis of diet-associated carotenemia. A good history and physical exam help narrow the differentials to tailor investigations. Laboratoryinvestigation reveals elevated serum carotene levels, often in the range of250 to 500 microgram/dl, with normal or slightly elevated liver enzymes. Measuring carotene levels in the skin could be facilitated by using reflection spectroscopy and Resonance Raman spectroscopy, both being noninvasive optical quantitative techniques for measuring carotenoid antioxidants in human skin in vivo. Plasma carotenoid status may be predicted by skin carotenoid status.[23][24]The bilirubinoxidase method has been reported to have misdiagnosed β-carotenemia as jaundice.[25]

A skin biopsy specimen could reveal autofluorescence in the superficial layer and a pemphigus-like pattern of intracellular autofluorescence.

Vitamin-A level is normalexcept in the rare case of inherited enzyme deficiency where the levelwill be low.[12][26]The evaluation must also include liver enzymes with bilirubin, thyroid function test, and screening for diabetes. Extensive investigations are seldom needed.

Treatment / Management

Cliniciansshould reassure the patients and their families as this is a benign condition unlikelyto lead to serious consequences. The mainstay of treatment is reducing the amount of carotene in the diet, which will eventually lead to theresolutionof skin pigmentation.[27]Parents should be informed that various green vegetables, such as green beans and spinach, are rich in carotene. Consultation with a dietitian may be helpfulin some cases.[14](B2)

Differential Diagnosis

Yellow skin discoloration hasbeen reported in uncontrolled diabetes with no history of excess carotene ingestion. Often, yellow pigmentation resolves by regulating blood sugar.[6]Hypercarotenemiamay also be seen in anorexia nervosa.[28][29][30]

Lycopenemia, a variant of carotenemia, is a yellow skin pigmentation caused by excessive tomato ingestion.[31][32]

Carotenemia has also beenassociatedwith a varietyof otherconditions, such as hypothyroidism, hypopituitarism, hypothalamic amenorrhea, liver disease, inborn errors of metabolism, and nephritic and nephrotic syndromes.[8]

In most of the above conditions, hypercarotenemia is probablyassociated with hyperlipidemiaor impairedconversion of carotene to vitamin A.[14]Ingestion of some other chemicals besides carotene could lead to yellow skin staining. Examples include saffron, quinacrine, tetryl, picric acid, and dinitrophenol.[8]Carotenemiawas also reported as a presentation forsystemic lambda-type AL amyloidosis.[33]Neurological degenerative diseases and brain tumors seem (through unclear mechanisms) to affect carotene metabolism and could lead to carotenemia inthe context ofnormal dietary carotene intake.[34]Some studies also suggested a correlation betweenbiliary dyskinesia, celiac disease, and high carotene levels.[35][36]

Prognosis

A low-carotene diet leads to the progressive disappearance of yellow skin coloration. Yellow skin could persist for several months, even after carotene levels return to normal due to the lipophilic nature of carotenoids. Carotenemia is a benign condition.[37]

Complications

The condition is relatively benign and seldom leads to any severe complications. Toxic retinopathy has been reported due to excesscanthaxanthin, a toxic carotenoid metabolite; however, changes are reversible, and no long-termsequelae have been reported.[38]Vitamin A poisoning does not usually occur even withvery high doses of carotene, as the conversion of carotene to vitamin A occurs slowly. However, a man who allegedly ate 6-7 pounds of carrots weekly was found to have constipation, hypercarotenemia, increased liver enzymes, and possible vitamin A toxicity.[39]

Deterrence and Patient Education

Reassurance should be given to parents of the pediatric population that diet-induced carotenemia is a reasonably benign condition requiring no treatment. However, if there is extreme parental anxiety, providers may inform parents about diets rich in carotene, and the child could bestarted on a carotene-deficient diet.

Enhancing Healthcare Team Outcomes

Carotenemia is best managed by an interprofessional healthcare team. Clinicians (MDs, DOs, NPs, and PAs) will be primarily responsible for making an accurate diagnosis, although the issue may first be noticed by patients, parents, or nursing staff. Once diagnosed, the clinician and nurse will continue to follow and counsel the patient and their family if necessary and monitor the patient's progress and response to corrective actions.Patient education in collaboration with a dietitian improves the outcome of the condition and prevents further unnecessary investigations.Clinicians should provide asimpleexplanation of the problem and how it is linked to the diet. Thiswill help with treatment compliance and appropriate food choices. Any interprofessional team member who notes a significant change in the patient's condition or a failure to respond to interventions should document their observations in the patient's health record and reach out to other team members as appropriate to enact corrective measures. This interprofessional approach will drive the best outcomes. [Level 5]

References

[1]

Leung AK. Benign carotenemia in children. Canadian family physician Medecin de famille canadien. 1989 Jan:35():81-3 [PubMed PMID: 21253272]

", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B1)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A2)"]').popover( { content: "A: Benefits outweigh the risks
2: Moderate level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B2)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A3)"]').popover( { content: "A: Benefits outweigh the risks
3: Low level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B3)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
3: Low level of evidence
", html: true, placement: "top", trigger:'hover' } ); });

[2]

Karthik SV, Campbell-Davidson D, Isherwood D. Carotenemia in infancy and its association with prevalent feeding practices. Pediatric dermatology. 2006 Nov-Dec:23(6):571-3 [PubMed PMID: 17156001]

Level 2 (mid-level) evidence

", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B1)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A2)"]').popover( { content: "A: Benefits outweigh the risks
2: Moderate level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B2)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A3)"]').popover( { content: "A: Benefits outweigh the risks
3: Low level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B3)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
3: Low level of evidence
", html: true, placement: "top", trigger:'hover' } ); });

[3]

COHEN. Observations on carotenemia. Annals of internal medicine. 1958 Feb:48(2):219-27 [PubMed PMID: 13509531]

", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B1)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A2)"]').popover( { content: "A: Benefits outweigh the risks
2: Moderate level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B2)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A3)"]').popover( { content: "A: Benefits outweigh the risks
3: Low level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B3)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
3: Low level of evidence
", html: true, placement: "top", trigger:'hover' } ); });

[4]

Chaparro RS, Carr E, Barron JL. Hypercarotenaemia or hypercarotenoidaemia. Annals of clinical biochemistry. 2003 May:40(Pt 3):280-2 [PubMed PMID: 12803843]

", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B1)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A2)"]').popover( { content: "A: Benefits outweigh the risks
2: Moderate level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B2)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A3)"]').popover( { content: "A: Benefits outweigh the risks
3: Low level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B3)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
3: Low level of evidence
", html: true, placement: "top", trigger:'hover' } ); });

[5]

Hsiao C, Clukay CJ. Orangeness-Peeling Back the Myths Behind Carotenemia. JAMA dermatology. 2017 Sep 1:153(9):873. doi: 10.1001/jamadermatol.2017.2673. Epub [PubMed PMID: 28903145]

", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B1)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A2)"]').popover( { content: "A: Benefits outweigh the risks
2: Moderate level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B2)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A3)"]').popover( { content: "A: Benefits outweigh the risks
3: Low level of evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B3)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
3: Low level of evidence
", html: true, placement: "top", trigger:'hover' } ); });

[6]

Julka S, Jamdagni N, Verma S, Goyal R. Yellow palms and soles: A rare skin manifestation in diabetes mellitus. Indian journal of endocrinology and metabolism. 2013 Oct:17(Suppl 1):S299-300. doi: 10.4103/2230-8210.119625. Epub [PubMed PMID: 24251193]

Level 3 (low-level) evidence

[7]

Rock CL. Carotenoids: biology and treatment. Pharmacology & therapeutics. 1997 Sep:75(3):185-97 [PubMed PMID: 9504139]

Level 3 (low-level) evidence

[8]

Lascari AD. Carotenemia. A review. Clinical pediatrics. 1981 Jan:20(1):25-9 [PubMed PMID: 7449242]

Level 3 (low-level) evidence

[9]

Attard-Montalto S, Evans N, Sherwood RA. Carotenaemia with low vitamin A levels and low retinol-binding protein. Journal of inherited metabolic disease. 1992:15(6):929-30 [PubMed PMID: 1293390]

Level 3 (low-level) evidence

[10]

Gangakhedkar A, Somerville R, Jelleyman T. Carotenemia and hepatomegaly in an atopic child on an exclusion diet for a food allergy. The Australasian journal of dermatology. 2017 Feb:58(1):42-44. doi: 10.1111/ajd.12414. Epub 2015 Oct 22 [PubMed PMID: 26490299]

[11]

Takita Y, Ichimiya M, Hamamoto Y, Muto M. A case of carotenemia associated with ingestion of nutrient supplements. The Journal of dermatology. 2006 Feb:33(2):132-4 [PubMed PMID: 16556283]

Level 3 (low-level) evidence

[12]

Sale TA, Stratman E. Carotenemia associated with green bean ingestion. Pediatric dermatology. 2004 Nov-Dec:21(6):657-9 [PubMed PMID: 15575851]

Level 3 (low-level) evidence

[13]

Priyadarshani AMB. Insights of hypercarotenaemia: A brief review. Clinical nutrition ESPEN. 2018 Feb:23():19-24. doi: 10.1016/j.clnesp.2017.12.002. Epub 2017 Dec 19 [PubMed PMID: 29460797]

[14]

McGowan R, Beattie J, Galloway P. Carotenaemia in children is common and benign: most can stay at home. Scottish medical journal. 2004 Aug:49(3):82-4 [PubMed PMID: 15462219]

Level 2 (mid-level) evidence

[15]

Patel H, Dunn HG, Tischer B, McBurney AK, Hach E. Carotenemia in mentally retarded children. I. Incidence and etiology. Canadian Medical Association journal. 1973 Apr 7:108(7):848-52 [PubMed PMID: 4707231]

[16]

Barua AB, Olson JA. beta-carotene is converted primarily to retinoids in rats in vivo. The Journal of nutrition. 2000 Aug:130(8):1996-2001 [PubMed PMID: 10917914]

Level 3 (low-level) evidence

[17]

Sharman IM. Hypercarotenaemia. British medical journal (Clinical research ed.). 1985 Jan 12:290(6462):95-6 [PubMed PMID: 3917738]

[18]

Thibault L, Roberge AG. The nutritional status of subjects with anorexia nervosa. International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition. 1987:57(4):447-52 [PubMed PMID: 3440720]

[19]

Gupta S, Bourke MJ, Burgess NG. Pain and Pigmentation: A Puzzling Presentation. Gastroenterology. 2021 Mar:160(4):1034-1036. doi: 10.1053/j.gastro.2020.10.027. Epub 2020 Oct 20 [PubMed PMID: 33096097]

[20]

Nakagami F,Nozato Y,Yamamoto K,Rakugi H, Carotenemia induced by iron deficiency. BMJ case reports. 2021 Jan 28; [PubMed PMID: 33509860]

Level 3 (low-level) evidence

[21]

Kayhan-Tetik B, Çaylan N. Betacarotenemia with isolated nose involvement in a child: a case report. Archivos argentinos de pediatria. 2019 Oct 1:117(5):e502-e504. doi: 10.5546/aap.2019.eng.e502. Epub [PubMed PMID: 31560500]

Level 3 (low-level) evidence

[22]

Singh S, Bhari N, Rai M, Gupta S. Orangechrome Due to Carotenemia Presenting as Trichrome Vitiligo. Journal of cutaneous medicine and surgery. 2018 Jul/Aug:22(4):422. doi: 10.1177/1203475418755764. Epub [PubMed PMID: 29927313]

[23]

Nguyen LM, Scherr RE, Linnell JD, Ermakov IV, Gellermann W, Jahns L, Keen CL, Miyamoto S, Steinberg FM, Young HM, Zidenberg-Cherr S. Evaluating the relationship between plasma and skin carotenoids and reported dietary intake in elementary school children to assess fruit and vegetable intake. Archives of biochemistry and biophysics. 2015 Apr 15:572():73-80. doi: 10.1016/j.abb.2015.02.015. Epub 2015 Mar 9 [PubMed PMID: 25765187]

[24]

Ermakov IV, Gellermann W. Optical detection methods for carotenoids in human skin. Archives of biochemistry and biophysics. 2015 Apr 15:572():101-111. doi: 10.1016/j.abb.2015.01.020. Epub 2015 Jan 28 [PubMed PMID: 25637655]

[25]

Kiuchi S, Ihara H, Koyasu M, Tani A, Hashizume N. A Case of β-Carotenemia Misdiagnosed as Jaundice by the Bilirubin Oxidase Method. Journal of nutritional science and vitaminology. 2019:65(5):451-454. doi: 10.3177/jnsv.65.451. Epub [PubMed PMID: 31666483]

Level 3 (low-level) evidence

[26]

Blaner WS, Li Y, Brun PJ, Yuen JJ, Lee SA, Clugston RD. Vitamin A Absorption, Storage and Mobilization. Sub-cellular biochemistry. 2016:81():95-125 [PubMed PMID: 27830502]

[27]

Arya V, Grzybowski J, Schwartz RA. Carotenemia. Cutis. 2003 Jun:71(6):441-2, 448 [PubMed PMID: 12839253]

[28]

Boland B, Beguin C, Zech F, Desager JP, Lambert M. Serum beta-carotene in anorexia nervosa patients: a case-control study. The International journal of eating disorders. 2001 Nov:30(3):299-305 [PubMed PMID: 11746290]

Level 2 (mid-level) evidence

[29]

Claudius K, Wissler K, Warnke A, Bröcker EB. [A "yellow" girl. Hypercarotenaemia in anorexia nervosa]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2005 Jul:3(7):559-60 [PubMed PMID: 15967016]

Level 3 (low-level) evidence

[30]

Crisp AH, Stonehill E. Hypercarotenaemia as a symptom of weight phobia. Postgraduate medical journal. 1967 Nov:43(505):721-5 [PubMed PMID: 6082700]

Level 3 (low-level) evidence

[31]

REICH P, SHWACHMAN H, CRAIG JM. Lycopenemia: a variant of carotenemia. The New England journal of medicine. 1960 Feb 11:262():263-9 [PubMed PMID: 14437033]

[32]

Gandhi M, Walton S, Wyatt EH. Hypercarotenaemia in a tomato soup faddist. BMJ (Clinical research ed.). 1988 Dec 24-31:297(6664):1635 [PubMed PMID: 3147767]

Level 3 (low-level) evidence

[33]

Hůlková H, Svojanovský J, Sevela K, Krusová D, Hanuš J, Vězda P, Souček M, Márová I, Feit J, Zambo I, Kovačevicova M, Vlášková H, Kostrouchová V, Novák P, Kostrouch Z, Elleder M. Systemic AL amyloidosis with unusual cutaneous presentation unmasked by carotenoderma. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2014 Mar:21(1):57-61. doi: 10.3109/13506129.2013.851076. Epub 2013 Nov 15 [PubMed PMID: 24479650]

Level 3 (low-level) evidence

[34]

Olmedilla B, Granado F, Blanco I. Hyper-beta-carotenemia unrelated to diet: a case of brain tumor. International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition. 1995:65(1):21-3 [PubMed PMID: 7657475]

Level 3 (low-level) evidence

[35]

Nishimura T. A correlation between carotenemia and biliary dyskinesia. The Journal of dermatology. 1993 May:20(5):287-92 [PubMed PMID: 8340533]

[36]

Bardella MT, Molteni N, Cesana B, Baldassarri AR, Binanchi PA. IgA antigliadin antibodies, cellobiose/mannitol sugar test, and carotenemia in the diagnosis of and screening for celiac disease. The American journal of gastroenterology. 1991 Mar:86(3):309-11 [PubMed PMID: 1900142]

[37]

Edigin E, Asemota IR, Olisa E, Nwaichi C. Carotenemia: A Case Report. Cureus. 2019 Jul 23:11(7):e5218. doi: 10.7759/cureus.5218. Epub 2019 Jul 23 [PubMed PMID: 31565621]

Level 3 (low-level) evidence

[38]

Hueber A, Rosentreter A, Severin M. Canthaxanthin retinopathy: long-term observations. Ophthalmic research. 2011:46(2):103-6. doi: 10.1159/000323813. Epub 2011 Feb 23 [PubMed PMID: 21346389]

[39]

Sansone RA, Sansone LA. Carrot man: a case of excessive beta-carotene ingestion. The International journal of eating disorders. 2012 Sep:45(6):816-8. doi: 10.1002/eat.22015. Epub 2012 Mar 19 [PubMed PMID: 22431270]

Level 3 (low-level) evidence

Carotenemia | Treatment & Management | Point of Care (2024)
Top Articles
Latest Posts
Recommended Articles
Article information

Author: Msgr. Benton Quitzon

Last Updated:

Views: 5885

Rating: 4.2 / 5 (43 voted)

Reviews: 90% of readers found this page helpful

Author information

Name: Msgr. Benton Quitzon

Birthday: 2001-08-13

Address: 96487 Kris Cliff, Teresiafurt, WI 95201

Phone: +9418513585781

Job: Senior Designer

Hobby: Calligraphy, Rowing, Vacation, Geocaching, Web surfing, Electronics, Electronics

Introduction: My name is Msgr. Benton Quitzon, I am a comfortable, charming, thankful, happy, adventurous, handsome, precious person who loves writing and wants to share my knowledge and understanding with you.